PT  - JOURNAL ARTICLE
AU  - Eric A. Wilson
AU  - Gabrielle Hirneise
AU  - Abhishek Singharoy
AU  - Karen S. Anderson
TI  - Total predicted MHC-I epitope load is inversely associated with population mortality from SARS-COV-2
AID  - 10.1101/2020.05.08.20095430
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.08.20095430
4099  - http://medrxiv.org/content/early/2020/06/14/2020.05.08.20095430.short
4100  - http://medrxiv.org/content/early/2020/06/14/2020.05.08.20095430.full
AB  - Polymorphisms in MHC-I protein sequences across human populations significantly impacts viral peptide binding capacity and thus alters T cell immunity to infection. Consequently, allelic variants of the MHC-I protein have been found to be associated with patient outcome to various viral infections, including SARS-CoV. In the present study, we assess the relationship between observed SARS-CoV-2 population mortality and the predicted viral binding capacities of 52 common MHC-I alleles. Potential SARS-CoV-2 MHC-I peptides were identified using a consensus MHC-I binding and presentation prediction algorithm, called EnsembleMHC. Starting with nearly 3.5 million candidates, we resolved a few hundred high-confidence MHC-I peptides. By weighing individual MHC allele SARS-CoV-2 binding capacity by population frequency in 23 countries, we discover a strong inverse correlation between the predicted population SARS-CoV-2 peptide binding capacity and observed mortality rate. Our computations reveal that peptides derived from the structural proteins of the virus produces a stronger association with observed mortality rate, highlighting the importance of S, N, M, E proteins in driving productive immune responses. These results bring to light how molecular changes in the MHC-I proteins may affect population-level outcomes of viral infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHLA frequency data was obtained from the Allele Frequency Net database. Coronavirus pandemic information was obtained from the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Mass spectrometry data was obtained from the UCSD MASSive database (MSV000084442). SARS-CoV-2 sequences were obtained from NCBI Virus database. http://www.allelefrequencies.net https://github.com/CSSEGISandData/COVID-19.git https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/